Attorney-only technical triage
KRAS inhibitors
Attorney Review Snapshot
New filing US20260297084A1 closely tracks your client reference US20260209252A1.
- Report ID
- IJ-2640-0032
- Prepared
- 2026-10-13
- Reviewer
- Instructing attorney
Recommendation
CONSULT
High match confidence
For review by the instructing patent attorney. Technical patent intelligence only; not a legal opinion.
01Relevant Claims & Passages
Claim 1; claims 34, 39, 40, 43, 50–56; claim 33; claims 2, 3, 6, 7, 10, 11, 13, 17, 20, 22, 26, 28, 32, 62
Paragraphs [0002], [0006], [0009]–[0010], [0034], [0036], [0038], [0040], [0042], [0058], [0074], [0084], [0093]–[0109]
Claim 12; claim 38; claim 39; claims 13, 17, 20, 21, 22
Source: published claim sets, both filings · 1 independent, 17 dependent, 30 paragraphs cited on the new filing
02Relevant Technical Feature
KRAS-inhibitor compounds feeding into pharmaceutical compositions and cancer-treatment methods.
Both filings claim small-molecule KRAS inhibitor platforms, then extend those platforms into compositions and therapeutic methods for cancer or KRAS-associated disease. The overlap is at the same mechanism level: compound genus, formulation, and use claims built around KRAS inhibition.
Client reference: US20260209252A1
03Material Distinction
The compound families are not the same. The new filing centers on a Formula (I) genus with specific substituent definitions and exemplified species, while the client reference claims a different selected compound set under claim 12.
04Why It May Warrant Review
The parallel claim structure raises a concrete portfolio question: whether the third-party KRAS family is close enough to warrant comparison against the client's pending or published KRAS inhibitor claims and how the different chemical series affect claim strategy.
Client reference published 2026-07-23
Application Information
New filing
KRAS inhibitors
- Publication
- US20260297084A1
- Applicant
- Incyte Corporation
- Publication date
- 2026-10-01
- Country
- US
Client reference
KRAS inhibitors
- Publication
- US20260209252A1
- Applicant
- Bristol-Myers Squibb Company
- Publication date
- 2026-07-23
- Country
- US
Patent intelligence only — not legal advice. No conclusion on infringement, validity, enforceability or freedom to operate. The attorney determines whether deeper technical or legal analysis is warranted.
Powered by IdeaJudge